By: IPP Bureau
Last updated : June 08, 2021 11:19 am
Financial support is being provided as a grant from the Government of India
As a part of this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufacturers are being upgraded with required infrastructure and technology
Under Atmanirbhar Bharat 3.0 Mission COVID Suraksha, the government of India through Biotechnology Industry Research Assistance Council (BIRAC) is accelerating the development and production of COVAXIN production by 10 crore doses per month.
To augment the capacity of Indigenous production of Covaxin under the Mission, the Department of Biotechnology, Government of India in April, 2021 provided financial support as grant to vaccine manufacturing facilities for increasing production capacities which is expected to reach more than 10 crore doses per month by September 2021.
As a part of this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufactures are being upgraded with required infrastructure and technology.
Financial support is being provided as a grant from the Government of India to the tune of approximately Rs. 65 crores to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
Haffkine Biopharmaceutical Corporation Limited, a state public sector undertaking under Government of Maharashtra, will have a capacity of 20 million doses per month once functional. The government of India is providing financial support of Rs. 65 crores as grant to make this facility ready for manufacturing.
Indian Immunologicals Limited (IIL), a facility under National Dairy Development Board (NDDB) is being provided a grant of Rs. 60 crores.
Bharat Immunologicals and Biologicals Limited (BIBCOL), a central public sector undertaking under the Department of Biotechnology, government of India is being supported with a grant of Rs. 30 crores to make the facility to manufacture 10-15 million doses per month.
Further, Gujarat Biotechnology Research Centre, Department of Science and Technology, government of Gujarat along with Hester Biosciences and OmniBRx has also firmed up its discussions with Bharat Biotech to scale up COVAXIN and to produce minimum 20 million doses per month. Technology transfer agreements have been finalized with all manufacturers.